All HER2-positive patients with BCRL, before developing lymphedema, were treated with the monoclonal antibody trastuzumab (TTZ), while only 19 (73%) women with HER2-positive tumors (n = 26) in the BCRL-negative group were treated with anti-HER2 therapy. The gene discussed is ERBB2; the disease is lymphedema.